A 12-week, randomized, double-blind, vehicle-controlled Phase II proof-of-concept study to evaluate the safety and efficacy of radezolid in individuals with moderate-to-severe acne vulgaris.

Trial Profile

A 12-week, randomized, double-blind, vehicle-controlled Phase II proof-of-concept study to evaluate the safety and efficacy of radezolid in individuals with moderate-to-severe acne vulgaris.

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Radezolid (Primary)
  • Indications Acne vulgaris
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 12 Oct 2017 New trial record
    • 10 Oct 2017 According to a Melinta Therapeutics media release, the trial is anticipated to start by the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top